News : DiaPrevent

In her comments in today’s quarterly report, Elisabeth Lindner, President and CEO of Diamyd Medical, describes the progress in the decisive Phase III studies with the Company’s lead drug candidate Diamyd®, and comments on the Company’s strategies and efforts to build a Nordic specialty pharmaceutical company.
”We have exciting times ahead of us with only one year to go before we have the results from our...

Diamyd Medical announces today that the company’s European Phase III study of the diabetes vaccine Diamyd® is now fully recruited. It is estimated that results from the study can be reported during spring 2011.
320 children and adolescents between 10 and 20 years of age and recently diagnosed with type 1 diabetes have now been identified and included in the company’s European Phase III study and have received...

Diamyd Medical announces today that the company has signed an agreement with Inclinix Inc., North Carolina, for accelerated recruitment of children and adolescents recently diagnosed with type 1 diabetes in the US Phase III study of the diabetes vaccine Diamyd®.
Diamyd Medical is conducting a global Phase III program with the diabetes vaccine Diamyd®, including in total 640 children and adolescents with...